Conference Reports for NATAP

Back

38th Annual Meeting of the European Association for the Study of the Liver   Istanbul, Turkey. March 28-April 1, 2003     COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL - (7/7/03)   Pegasys News: 4 year follow-up; study of treating cirrhotics; study of Peg-Intron non-responders - (7/7/03)   Entecavir, new HBV drug, Suppresses Lamivudine Resistance - (7/7/03)   OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION (LDLT) : GRAFT SURVIVAL IS POOR ESPECIALLY IN HCV RECIPIENTS - (3/26/03)   A RANDOMISED DOUBLE-BLIND PHASE II STUDY OF LAMIVUDINE (LAM) COMPARED TO LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL (ADV) FOR TREATMENT NAIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB) : WEEK 52 ANALYSIS - (3/26/03)   SIMVASTATIN AMMELIORATES THE INCREASED HEPATIC VASCULAR TONE IN PATIENTS WITH CIRRHOSIS - (3/26/03)   TENOFOVIR EFFECTIVELY INHIBITS VIRAL REPLICATION IN DIFFERENT PATIENT GROUPS WITH LAMIVUDINE RESISTANT HBV INFECTION - (3/26/03)   LIVER FIBROSIS REGRESSES BETTER WITH PEGINTERFERON ALPHA AND URSODEOXYCHOLIC ACID TREATMENT THAN SPONTANEOUS RECOVERY - (3/26/03)   EFFECT OF HBV AND HCV COINFECTION ON ANTI-VIRAL T CELL RESPONSES - (3/26/03)   A RANDOMIZED CONTROLLED TRIAL OF PEGYLATED-INTERFERON ALPHA-2B + RIBAVIRIN VS INTERFERON ALPHA-2B + RIBAVIRIN IN HIV CO-INFECTED PATIENTS - (3/26/03)   COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL - (3/26/03)   PREDICTORS OF VIROLOGIC RESPONSE IN COMBINATION THERAPY WITH INTERFERON (IFN) ALFA 2B PLUS RIBAVIRIN OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION (LT) - (3/26/03)   PREDCTIVE FACTORS OF HCC RECURRENCE AFTER LIVER TRANSPLANTATION (OLT) : AN INTERIM ANALYSIS - (3/26/03)   Factors Associated With recurrence After Liver transplantation For Hepatocellular Carcinoma - (3/26/03)   A STUDY OF THE PRESENCE OF HCV RNA IN SEMEN OF PATIENTS WITH CHRONIC HCV INFECTION - (3/26/03)   EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN FOR 24 WEEKS IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C FOLLOWED BY MONO OR COMBINATION THERAPY FOR 22 WEEKS: PRELIMINARY ANALYSIS OF AN OPEN, MULTICENTER, RANDOMIZED TRIAL - (3/25/03)   Entecavir for HBV in Lamivudine Failures - (3/25/03)   EFFICIENCY OF DNA VACCINE IN ASSOCIATION WITH LAMIVUDINE FOR CHRONIC HEPATITIS B THERAPY - (3/25/03)   THE EFFECT OF PEGINTERFERON ALFA-2A (40 KD) ON LIVER HISTOLOGY IN CHRONIC HEPATITIS C: A META-ANALYSIS OF INDIVIDUAL PATIENTS DATA - (3/25/03)   Clevudine, New Drug for HBV - (3/25/03)   PHARMACOKINETICS OF PEGINTERFERON ALFA-2A (40KD, PEGASYS) COMPARED TO PEGINTERFERON ALFA-2B (12KD, PEGINTRON) IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) - (3/25/03)   Study Suggests More Than 48 Weeks Therapy for Patients with high baseline viral loads, HCV genotype 1, and cirrhosis may be necessary - (3/25/03)